Brenntag Specialties becomes exclusive distributor for INOFEA services in EMEA

31-Oct-2022 - Germany

Brenntag announced the exclusive partnership with INOFEA to promote the pharmaceutical applications of its enzyme technology in EMEA.

As part of the exclusive partnership, Brenntag and INOFEA will provide support and services to enable customers to get the most out of INOFEA’s technology in their applications, such as protecting and enhancing the performance of their enzymes. Brenntag will leverage its global reach to promote INOFEA’s products and services within the pharmaceutical industry, including the manufacturers of APIs, biosimilars, intermediates, diagnostics and medical devices.

INOFEA has developed the enzzen® technology, enhancing enzyme stability, enabling recyclability and easy recovery in manufacturing steps. Enzymes earn a broader substrate range and achieve an extraordinary reactivity by enhancing reaction rate and selectivity. Thus, customers need less raw materials for synthesis, less energy during the production process and can benefit from lower waste production and solvents used in biocatalytic processes.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances